Clinical trial NCT03250130: Hypnosis for Patients Treated With Adjuvant Chemotherapy for Breast Cancer(HYPNOVAL)
Official title: Medical Ericksonian Hypnosis on Patients Treated With Adjuvant Chemotherapy for Breast Cancer at the ICM Val d'Aurelle - Montpellier: a Feasibility Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Breast Cancer
Lead sponsor: Institut du Cancer de Montpellier - Val d'Aurelle
Sponsor class: OTHER
First posted: 2017-08-15
Enrollment: 35
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: PREVENTION

Brief summary: The main objective is to assess the feasibility of an intervention based on medical Ericksonian hypnosis as a complementary therapy in patients treated with surgery after a diagnosis of breast cancer, followed by an indication of adjuvant chemotherapy and radiotherapy

Detailed description: In the field of management of cancer, many approaches have been used since tens of years, particularly in regard of pain management, both in achieving surgical or invasive procedures in the pain induced by the disease itself. the investigators owe the first description in 1829 Chapelin and col who used hypnosis in a patient with breast cancer in which a mastectomy should be performed. Meta-analysis (2000) showed the positive impact of analgesia obtained through hypnosis on the perception of pain intensity. In children in whom regular venous punctures is performed, using hypnosis seems indisputable on the management of anticipatory anxiety, leading to a better experience of the act itself. Regarding the nausea and vomiting induced by chemotherapy, numerous studies are old, not always randomized and performed often before the era of the setrons; but seems favorable impact on anticipated nausea and vomiting, the updated studies should emerge on the issue of delayed emesis which remain a serious adverse event and not completely resolved. Mark to improve the EORTC validated tools of quality of life measurement widely used for example in ovarian cancer.

The impact of hypnosis on the quality of life or the side effects of treatment or rehospitalization for toxicity remains controversial (Judson, 2011). A meta-analysis combining the tests carried out before and after the era of setrons (Richardson, 2007) concluded that the effectiveness of the anticipated nausea and vomiting.

In this context,the investigators proposed to conduct a feasibility study to evaluate the role and impact of medical Ericksonian hypnosis on acute and delayed adverse event (incl nausea and vomiting) in female patients treated by adjuvant chemotherapy for breast cancer.

The main objective is to assess the feasibility of an intervention based on medical Ericksonian hypnosis as a complementary therapy in patients treated with surgery after a diagnosis of breast cancer, followed by an indication of adjuvant chemotherapy and radiotherapy

Eligibility criteria: Inclusion Criteria:

* • Female, age \> 18 years-old

  * Without previous practice of hypnosis
  * Patient with diagnosis of breast cancer
  * Patient receiving an adjuvant chemotherapy for at least 3 months with an indication of radiotherapy after chemotherapy
  * Patient accepting the principle of the study with a signed written informed consent
  * Patient affiliated to French Social Security

Exclusion Criteria:

* • Male

  * Age \< 18 years
  * Patient refusing hypnosis
  * Pregnancy, breast-feeding, or lack of effective contraception in female patients with reproductive potential.
  * Patient with psychological or mental disorders under psychotropic treatments (lithium, neuroleptics)
  * Not ability to speak and read French, deaf and/or mute

Primary outcomes:
measure: proportion of patients rated as being compliant to self-hypnosis
timeFrame: through study completion, an average of 2 years
Secondary outcomes:
measure: Impact of hypnosis on the tolerance of the CT
timeFrame: through study completion, an average of 2 years
Other outcomes:
Locations:
city: Montpellier
country: France
facility: Institut régional du Cancer de montpellier
Study officials:
affiliation: Institut régional du Cancer de Montpellier
name: Michel FABBRO
role: STUDY_CHAIR
References: